Bahng H, Lee J H, Suh C, Ahn J H, Kim S B, Kim S W, Lee K H, Lee J S, Kim W K, Park C J, Chi H S, Kim S H
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Med Sci. 1998 Oct;13(5):541-4. doi: 10.3346/jkms.1998.13.5.541.
Aplastic anemia is a rare side-effect associated with ticlopidine therapy. We report two cases of severe aplastic anemia developed after the use of ticlopidine. A 51-year-old woman took ticlopidine at 500 mg/day for 49 days to prevent a secondary stroke. She developed fever and dizziness within 49 days of initiating ticlopidine therapy. A 70-year-old woman was started on ticlopidine after coronary stent insertion. Fifty days after starting ticlopidine, she developed fever and dizziness. Both patients showed pancytopenia and were diagnosed as aplastic anemia which were confirmed by bone marrow examination. Both patients were hospitalized and received antibiotics, blood products and hematopoietic growth factors. Four and seven weeks after the withdrawal of ticlopidine, the hematologic parameters of each patient improved. A complete blood count should be monitored during ticlopidine therapy to check for cytopenia.
再生障碍性贫血是噻氯匹定治疗相关的一种罕见副作用。我们报告两例使用噻氯匹定后发生严重再生障碍性贫血的病例。一名51岁女性每天服用500毫克噻氯匹定，持续49天以预防二次中风。在开始噻氯匹定治疗的49天内，她出现发热和头晕。一名70岁女性在冠状动脉支架置入后开始服用噻氯匹定。开始服用噻氯匹定50天后，她出现发热和头晕。两名患者均表现为全血细胞减少，经骨髓检查确诊为再生障碍性贫血。两名患者均住院并接受了抗生素、血液制品和造血生长因子治疗。停用噻氯匹定4周和7周后，每名患者的血液学参数均有改善。在噻氯匹定治疗期间应监测全血细胞计数以检查是否存在血细胞减少。
